Analysts Set United Therapeutics Co. (NASDAQ:UTHR) Price Target at $382.08

Shares of United Therapeutics Co. (NASDAQ:UTHR) have earned an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $388.25.

A number of equities analysts recently issued reports on UTHR shares. The Goldman Sachs Group upped their price target on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. HC Wainwright upped their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Argus lifted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. LADENBURG THALM/SH SH boosted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, UBS Group raised their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $358.21 on Tuesday. United Therapeutics has a 1 year low of $221.53 and a 1 year high of $417.82. The company has a market capitalization of $15.99 billion, a price-to-earnings ratio of 15.73, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. The business has a 50-day moving average of $362.39 and a two-hundred day moving average of $360.91.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,743,122.70. This represents a 17.34 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares in the company, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 114,164 shares of company stock valued at $41,671,293. 11.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds have recently added to or reduced their stakes in UTHR. Signaturefd LLC increased its position in United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 30 shares during the period. Parallel Advisors LLC grew its holdings in United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock worth $385,000 after acquiring an additional 30 shares during the period. Anchor Investment Management LLC lifted its holdings in United Therapeutics by 12.0% in the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 30 shares during the period. Great Lakes Advisors LLC boosted its position in shares of United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock worth $697,000 after purchasing an additional 31 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund grew its stake in shares of United Therapeutics by 0.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after purchasing an additional 33 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.